Literature DB >> 15550842

Surgical pathological staging of breast cancer by sentinel lymph node biopsy with special emphasis on the histological work-up of axillary sentinel lymph nodes.

Gábor Cserni1.   

Abstract

Axillary nodal status assessed by traditional histological methods is a proven independent prognostic factor in breast cancer. Sentinel lymph node biopsy is a surgical pathologic staging procedure that not only allows the selective removal of the most likely sites of lymphogenic metastases, but also enables upstaging of breast carcinoma by detecting nodal involvement undetected by standard methods of nodal staging. This review highlights the upstaging potential of sentinel node biopsy. It also suggests that incomplete reporting of the pathological methods may make the comparisons of results from different studies difficult. The article also describes a few methods that have been claimed optimal but are probably not, and it formulates basic considerations for building up a histological protocol that can identify all metastases larger than 2 mm, which are of unquestionable prognostic relevance. These considerations are also useful for the detection of micrometastases. Issues of pathological reporting of sentinel nodal findings are also highlighted, with emphasis on the lack of standardization and on the differentiation of isolated tumor cells from micrometastases. Finally the stepwise building up of our current histology protocol and our experience gained since the introduction of sentinel node biopsy in 1997 is also briefly summarized.

Entities:  

Mesh:

Year:  2004        PMID: 15550842     DOI: 10.1007/bf02984544

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   4.239


  1 in total

1.  Relationship between viral factors, axillary lymph node status and survival in breast cancer.

Authors:  Ju-Hsin Tsai; Chun-Sen Hsu; Chung-Hung Tsai; Jang-Ming Su; Yin-Tso Liu; Min-Hsiung Cheng; James Cheng-Chung Wei; Fong-Lin Chen; Chi-Chiang Yang
Journal:  J Cancer Res Clin Oncol       Date:  2006-07-25       Impact factor: 4.553

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.